This website uses cookies. For more information please contact us or consult our privacy policy.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Kristian Wiggert
Kristian E. Wiggert
London +44 20 7067 2280 Download V-card

Kristian Wiggert advises companies, financial institutions and investment funds in Europe and the US on complex cross-border transactions.  Having practiced in London since 2000, he understands the commercial issues clients face when they operate internationally.  According to Chambers UK (2014-2015) he is "very knowledgeable” and has “an eye for the legal as well as the commercial side of a transaction."  He is "good at handling novel problems quickly and efficiently and tailoring his advice to the needs of individual clients."

  • Advised Vernalis plc on its acquisition of the US rights to MOXATAG® (amoxicillin extended-release tablets) from Pragma Pharmaceuticals, LLC. 
  • Advised Horizon Discovery Group plc, an AIM listed international life science company supplying research tools and services to organizations engaged in genomics research and the development of personalized medicines, on:
  • Advised Lombard Medical, Inc., a Nasdaq-listed medical device company, on:
  • Advised Oxford BioMedica plc, a Main Market listed gene based biopharmaceutical company, on:
    • a $55 million secured debt facility with Oaktree Capital Management - Strategic Credit Strategy.
    • a follow-on financing to raise gross proceeds of £11.5 million by way of a placing and subscription of new ordinary shares; 
    • a follow-on financing to raise £8.1 million pursuant to a placing of new ordinary shares with both new and existing investors; and
    • a $50 million secured loan facility from a subsidiary of Oberland Capital Healthcare.

Memberships and Affiliations

  • American Bar Association
  • Chambers UK, Corporate/M&A: Mid-Market (2012-2015)
  • Legal 500 UK, Flotations: Small and Mid-Cap (2014, 2016)    
  • Legal 500 UK, Equity Capital Markets (2013, 2016)
  • Legal 500 UK, M&A - Premium Deals (2012-2014)
  • Legal 500 UK, Pharmaceuticals & Biotechnology (2012)